Platelet-Rich Plasma Versus Botulinum Toxin for Refractory Overactive Bladder: A Randomized Trial

NARecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

April 15, 2026

Study Completion Date

April 15, 2026

Conditions
Overactive Bladder SyndromeUrinary Urge IncontinenceDetrusor Overactivity
Interventions
BIOLOGICAL

Platelet-Rich Plasma

Autologous platelet-rich plasma prepared from approximately 50 milliliters of venous blood using a two-step centrifugation protocol. Ten milliliters of platelet-rich plasma are obtained and injected into the sub-urothelial layer of the bladder wall during cystoscopy under anesthesia.

DRUG

Intravesical Botulinum Toxin Injection

Botulinum toxin (100 units) reconstituted in 10 milliliters of saline and injected into the bladder detrusor muscle at multiple sites under cystoscopic guidance, sparing the trigone.

Trial Locations (1)

13511

RECRUITING

Benha University Hospital, Faculty of Medicine, Department of Urology, Banhā

All Listed Sponsors
lead

Benha University

OTHER